ASXL1 and B-cell chronic lymphocytic leukemia: To further elucidate the in vivo efficacy of PARPi treatment, mice transplanted with Asxl1−/−Ezh2−/− CLL were treated with olaparib 1 week after tertiary transplantation (Figure 4J).